Holen Sie sich die Stockscreener-App
48.87
4.56%
2.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$46.74
Offen:
$46.85
24-Stunden-Volumen:
3.36M
Relative Volume:
2.86
Marktkapitalisierung:
$5.77B
Einnahmen:
$3.22M
Nettoeinkommen (Verlust:
$-576.40M
KGV:
-8.8533
EPS:
-5.52
Netto-Cashflow:
$-407.05M
1W Leistung:
+0.45%
1M Leistung:
-1.99%
6M Leistung:
-5.69%
1J Leistung:
+36.81%
1-Tages-Spanne:
$46.85
$50.32
1-Wochen-Bereich:
$45.66
$50.32
52-Wochen-Spanne:
$36.24
$110.25
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
48.87 | 5.77B | 3.22M | -576.40M | -407.05M | -5.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics (CYTK) Stock Rises on New Licensing Deal - GuruFocus.com
Why Cytokinetics Stock Was a Nearly 5% Winner Today - MSN
Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp - The Globe and Mail
Cytokinetics stock rises on Sanofi's rights acquisition By Investing.com - Investing.com Canada
HC Wainwright Reiterates "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Sanofi: acquisition of aficamten rights for China - Marketscreener.com
Cytokinetics, Incorporated Announces Sanofi Acquires Exclusive Rights to Develop and Commercialize Aficamten from Corxel Pharmaceuticals - Marketscreener.com
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China - The Manila Times
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Franklin Resources Inc. Sells 1,820,114 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Given New $82.00 Price Target at Royal Bank of Canada - MarketBeat
Cytokinetics CFO to assume additional role after officer departs By Investing.com - Investing.com Australia
Geode Capital Management LLC Raises Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Wendall Wierenga Sells 742 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics director Wendall Wierenga sells $36,068 in stock By Investing.com - Investing.com Canada
Cytokinetics CFO to assume additional role after officer departs - Investing.com
Cytokinetics' SWOT analysis: aficamten's potential reshapes cardiac drug stock - Investing.com
Cytokinetics' SWOT analysis: aficamten's potential reshapes cardiac drug stock By Investing.com - Investing.com UK
A Look At The Intrinsic Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) - Simply Wall St
Cytokinetics director John Henderson sells $89,747 in stock By Investing.com - Investing.com Australia
Cytokinetics director John Henderson sells $89,747 in stock - Investing.com India
Insider Sell: Fady Malik Sells 7,300 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Cytokinetics EVP sells shares worth $369,639 By Investing.com - Investing.com Nigeria
Cytokinetics EVP sells shares worth $369,639 - Investing.com India
Two Sigma Advisers LP Makes New $11.34 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
BNP Paribas Financial Markets Reduces Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report? - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ:CYTK) Stock Holdings Lifted by Janus Henderson Group PLC - MarketBeat
FDA Sets Goal Date for Lymphoma Drug Columvi - Managed Healthcare Executive
Redmile Group LLC Sells 14,751 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug - MSN
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Melqart Asset Management UK Ltd - MarketBeat
HighVista Strategies LLC Invests $531,000 in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics Grants New Hires $1.8M+ Stock Options and RSU Package as Employment Incentive | CYTK Stock News - StockTitan
FDA Sets Goal Date for Cardiomyopathy Drug, Aficamten - Managed Healthcare Executive
FDA Accepts Cytokinetics' Application for Cardiovascular Drug - Yahoo Finance
Daily Digest: Sale of former Raiders HQ falls through; Oakland's credit rating cut - The Business Journals
Stock Watch: AHA Conference Disappointments - Scrip
Cytokinetics Launches Major Phase 3 Heart Failure Trial with 1,800 Patient Target | CYTK Stock News - StockTitan
FDA kicks off review of Cytokinetics' aficamten for HCM - pharmaphorum
Erste Asset Management GmbH Invests $3.16 Million in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
FDA accepts Cytokinetics' New Drug Application for HCM By Investing.com - Investing.com Canada
The Manufacturers Life Insurance Company Boosts Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics to Present at Evercore ISI and Piper Sandler Healthcare Conferences - StockTitan
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy - The Manila Times
Cytokinetics' HCM Drug Aficamten Advances with FDA Filing Acceptance, 2025 Review Date - StockTitan
Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date - Yahoo Finance
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytokinetics Inc-Aktie (CYTK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WIERENGA WENDALL | Director |
Dec 16 '24 |
Sale |
48.61 |
742 |
36,069 |
24,559 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):